Jones Day's Maureen Bennett elected to the Lambda Legal Board
Maureen Bennett, partner in Jones Day's Health Care & Life Sciences Practice and resident in the Firm's Boston and San Francisco offices, has been elected to the Lambda Legal Board of Directors. Her three-year term begins this month.
We are thrilled to have Maureen join Lambda Legal's Board of Directors," said Kevin Jennings, CEO of Lambda Legal. "She brings a wealth of knowledge and experience that will help chart our vital work of achieving full recognition of the civil rights of LGBTQ+ people and everyone living with HIV."
Lambda Legal is the oldest and largest national legal organization whose mission is to achieve full recognition of the civil rights of lesbians, gay men, bisexuals, transgender people, and everyone living with HIV through impact litigation, education, and public policy work.
"I am very excited about this opportunity," said Ms. Bennett. "Jones Day has been a long-time sponsor and supporter of the important work undertaken by Lambda Legal and we are currently handling pro bono matters in collaboration with the organization. It is an honor to follow in the footsteps of our colleague Curt Kirschner, and I hope to continue to grow the Firm's relationship with Lambda Legal and support its critical mission."
Ms. Bennett is co-chair of the Firm's LGBTQ+ Affinity Group and is Chair of the Boston Office Diversity Committee.
Ms. Bennett is a recognized leader in the global clinical trial regulatory field and was named by The American Lawyer as a 2021 "Northeast Trailblazer." For more than 20 years, she has provided counsel to life sciences and health care clients on a wide range of regulatory and contracting matters in support of their clinical development programs. She has been instrumental in advising Jones Day's clients in their deployment of clinical trials, utilizing novel technologies on a global basis. In 2020/21, Ms. Bennett supported several clients involved in critical clinical trials in support of therapeutics and vaccines to address COVID-19. Several of her recent representations have helped major players in the health care and life sciences industry quickly adapt to the implementation of stay-at-home and hybrid clinical trials. In addition, she regularly advises pharmaceutical companies in connection with the regulatory requirements associated with the development and use of digital tools, such as apps, wearable devices, and patient-reported outcome tools in clinical trials.
She is a former co-chair of the Boston Bar Association's Health Care Section and a regular speaker at industry conferences.
